Page last updated: 2024-11-07

disuccinimidyl tartarate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

disuccinimidyl tartarate: RN given refers to (R-(R*,R*)-isomer); structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124912
SCHEMBL ID111364
MeSH IDM0069257

Synonyms (17)

Synonym
disuccinimidyl tartrate
bis(2,5-dioxopyrrolidin-1-yl) (2r,3r)-2,3-dihydroxybutanedioate
62069-75-4
2,5-pyrrolidinedione, 1,1'-((2,3-dihydroxy-1,4-dioxo-1,4-butanediyl)bis(oxy))bis-, (r-(r*,r*))-
disuccinimidyl tartarate
NXVYSVARUKNFNF-NXEZZACHSA-N
(2r,3r)-bis(2,5-dioxopyrrolidin-1-yl) 2,3-dihydroxysuccinate
SCHEMBL111364
DTXSID10211120
disuccinimidyl l-tartrate
disuccinimidyl-l-tartrate
AKOS032950050
bis(2,5-dioxopyrrodilin-1-yl)(2r,3r)2,3dihydroxybutanedioate
mfcd03788224
H11463
di(n-succinimidyl) l-tartrate
D5500
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (31.58)18.7374
1990's9 (47.37)18.2507
2000's2 (10.53)29.6817
2010's2 (10.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.46 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]